Mexicor capsules 100mg, No. 20

- ischemic heart disease (as part of complex therapy);
- complex therapy of ischemic stroke;
- encephalopathy;
- mild to moderate cognitive impairment.

Inside. Treatment is started with a dose of 100 mg (1 capsule) 3 times a day, gradually increasing the dose depending on the clinical course of the disease and the tolerance of the therapy. The maximum daily dose should not exceed 800 mg, single 200 mg. It is advisable to distribute the daily dose of the drug into several doses during the day. The course therapy with the drug is completed gradually, reducing the daily dose of the drug by 100 mg (1 capsule).
The duration of the course of therapy in patients with ischemic heart disease and cerebral circulation disorders is at least 1.5-2 months. Repeated courses (on the recommendation of a doctor), preferably in the spring-autumn periods.
In the complex therapy of discirculatory encephalopathy, mild and moderate cognitive disorders, the drug is prescribed without limiting the course of treatment in duration, at a dose of 100 mg 3-4 times a day.

Active substance:

Ethylmethylhydroxypyridine succinate in terms of 100% substance - 100 mg,

Excipients:

potato starch, povidone (low molecular weight medical polyvinylpyrrolidone 12600 ± 2700), lactose (milk sugar), magnesium stearate, microcrystalline cellulose; hard gelatin capsules No. 2 (titanium dioxide E171, gelatin, sunset yellow dye E PO, quinoline yellow dye E 104).

Hypersensitivity to the drug, acute violations of liver and kidney function, age up to 18 years (efficacy and safety have not been established), pregnancy, breastfeeding period.

Trade name: MexicorЃ

International non-proprietary or grouping name : ethylmethylhydroxypyridine succinate

Dosage form : capsules

Composition : 1 capsule contains

Active substance:

Ethylmethylhydroxypyridine succinate in terms of 100% substance - 100 mg,

Excipients:

potato starch, povidone (low molecular weight medical polyvinylpyrrolidone 12600 ± 2700), lactose (milk sugar), magnesium stearate, microcrystalline cellulose; hard gelatin capsules No. 2 (titanium dioxide E171, gelatin, sunset yellow dye E PO, quinoline yellow dye E 104).

Description : yellow hard gelatin capsules No. 2. The content of the capsules is a granulate containing granules and powder of white or white with a yellowish sheen.

Pharmacotherapeutic group : antioxidant agent

ATX CODE —01?¬

Pharmacological properties

Pharmacodynamics
MexicorЃ reduces the manifestations of oxidative stress by inhibiting free radical lipid peroxidation and increasing the activity of the antioxidant enzyme system. MexicorЃ improves cellular energy metabolism by activating the energy-synthesizing functions of mitochondria, enhancing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energy-synthesizing effect of the drug is associated with an increase in the delivery and consumption of succinate by cells, the realization of the phenomenon of rapid oxidation of succinic acid by succinate dehydrogenase, as well as with the activation of the mitochondrial respiratory chain. When MexicorЃ is dissociated in a cell into succinate and a 3-hydroxypyridine derivative (base), the base exhibits an antioxidant effect that stabilizes cell membranes and restores the functional activity of cells.Reduces the viscosity of the cell membrane, increases its fluidity and has a modulating effect on membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which helps to maintain the structural and functional integrity of biomembranes, improves the transport of neurotransmitters and synaptic transmission. Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.improves the transport of neurotransmitters and synaptic transmission. Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.improves the transport of neurotransmitters and synaptic transmission. Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.
Improves the functional state of the ischemic myocardium, the contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in case of reversible cardiac dysfunction, which is a significant reserve for increasing the contractility of the heart in patients with ischemic heart disease complicated by heart failure.
In patients with stable exertional angina, it increases exercise tolerance and antianginal activity of nitro drugs, improves the rheological properties of blood. The addition of MexicorЃ to standard therapy for coronary heart disease improves the clinical condition of patients, increasing exercise tolerance and improving quality of life.
Mexicor stabilizes the membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculation disorders in the early stages of atherogenesis, has a hypolipidemic effect, reduces total cholesterol and low density lipoprotein (LDL).
Mexicor has a neuroprotective effect on the functional activity and metabolism of the ischemic brain, increases the stability of the cerebral circulation in conditions of hypoperfusion, and prevents a decrease in cerebral blood flow in the reperfusion period after ischemia. The drug promotes adaptation to the damaging effect of ischemia, inhibiting the depletion of carbohydrate reserves, blocking the post-ischemic decline in the utilization of glucose and oxygen by the brain and preventing the progressive accumulation of lactate. At the same time, the indicators of autoregulatory reactions of cerebral vessels improve.
MexicorЃ has nootropic properties, prevents and reduces learning and memory impairments that occur in acute and chronic vascular diseases of the brain, with mild and moderate cognitive impairments of various origins, has an antioxidant effect, increases concentration and performance.
The inclusion of the drug MexicorЃ in the complex therapy of patients with acute cerebrovascular accident reduces the severity of clinical manifestations of stroke and improves the course of the rehabilitation period.
MexicorЃ has a selective, unaccompanied sedation and muscle relaxation, anxiolytic effect, eliminates anxiety, fear, tension, anxiety, increases adaptation and emotional status.

Pharmacokinetics
After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract. It is quickly distributed in organs and tissues. The time to reach the maximum concentration (Tmax) in the blood plasma is 0.46-0.50 hours. The average time of drug distribution in the body is 4.9-5.2 hours. It is metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate - formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite - pharmacologically active, is formed in large quantities and is found in urine 1-2 days after taking the drug; 3rd - excreted in large quantities by the kidneys; 4th and 5th - glucuron conjugates. The half-life is 4.7-5 hours. On average, 0 is excreted by the kidneys in 12 hours,3% unchanged drug and 50% in the form of glucuronoconjugate of the administered dose. It is most intensively excreted during the first 4 hours after taking the drug. Renal excretion rates of unchanged drug and metabolites have significant individual variability.

Indications for use
- ischemic heart disease (as part of complex therapy);
- complex therapy of ischemic stroke;
- encephalopathy;
- mild to moderate cognitive impairment.

Contraindications

Hypersensitivity to the drug, acute violations of liver and kidney function, age up to 18 years (efficacy and safety have not been established), pregnancy, breastfeeding period.

Dosing and Administration
Inside. Treatment is started with a dose of 100 mg (1 capsule) 3 times a day, gradually increasing the dose depending on the clinical course of the disease and the tolerance of the therapy. The maximum daily dose should not exceed 800 mg, single 200 mg. It is advisable to distribute the daily dose of the drug into several doses during the day. The course therapy with the drug is completed gradually, reducing the daily dose of the drug by 100 mg (1 capsule).
The duration of the course of therapy in patients with ischemic heart disease and cerebral circulation disorders is at least 1.5-2 months. Repeated courses (on the recommendation of a doctor), preferably in the spring-autumn periods.
In the complex therapy of discirculatory encephalopathy, mild and moderate cognitive disorders, the drug is prescribed without limiting the course of treatment in duration, at a dose of 100 mg 3-4 times a day.

Side effect

The drug is usually well tolerated. In rare cases, there may be allergic reactions, dyspeptic disorders, nausea and dry mouth; diarrhea that quickly disappear on their own or when the drug is discontinued. With prolonged use, the manifestation of flatulence, sleep disturbances (drowsiness or disturbed falling asleep) is possible.

Overdose
Due to the low toxicity of the drug, overdose is unlikely. In case of an accidental overdose, symptoms of sleep disturbance may occur - drowsiness, insomnia.
Treatment is symptomatic.

Interaction with other drugs
- enhances the effect of antiepileptic drugs (carbamazepine), antiparkinsonian drugs (levodopa) and benzodiazepine anxiolytics;
- increases the antianginal activity of nitro drugs and antihypertensive ACE inhibitors and beta-blockers;
- reduces the toxic effects of ethanol.

Special instructions
During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Release form
Capsules of 100 mg. 10 capsules in a blister strip made of polyvinyl chloride film and aluminum foil. 2 or 5 contour packs, together with instructions for use, are placed in a cardboard box.

Storage conditions
List B. Store in a dry, dark place at a temperature not exceeding 25 ? C. Keep out of the reach of children.

Shelf life is
3 years. Do not use after the expiration date printed on the package.

Terms of dispensing from pharmacies
Prescription.